XLON
TSTL
Market cap271mUSD
Oct 09, Last price
432.50GBP
1D
0.58%
1Q
11.61%
Jan 2017
177.24%
IPO
867.30%
Name
Tristel PLC
Chart & performance
P/E
31.26
P/S
4.47
EPS
0.14
Div yield, %
3.32%
Shrs. gr., 5y
0.49%
Rev. gr., 5y
7.96%
Revenues
46m
+10.80%
Net income
7m
+2.33%
CFO
10m
-5.24%
Dividend
Mar 19, 20265.68 GBP/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Operating both within the United Kingdom and globally, Tristel plc specializes in the development, production, and distribution of products designed for infection control. Its business is structured into three primary divisions: Hospital Medical Device Decontamination, Hospital Environmental Surface Disinfection, and a third, unnamed 'Other' segment. Under its proprietary Tristel brand, the firm provides a comprehensive range of medical instrument disinfection solutions. These cater to a diverse array of applications, such as airway management, cardiology, ENT, endoscopy, gastrointestinal physiology, laboratory use, ophthalmology, phlebotomy, reproductive health/IVF, surface disinfection, ultrasound, urology, and women's health, alongside other related offerings. Established in 1993, Tristel plc maintains its headquarters in Snailwell, United Kingdom.
Key people
Bruno Holthof
Non-Executive Chairman of the Board · since 2019
Elizabeth A. Dixon
Group Finance Director, Executive Director · since 2010
Paul C. Swinney
Chief Executive, Executive Director
Company Secretary, Non-Executive Director · since 2010
Bruce C. Green
Non-Executive Director · since 2008
Tom Jenkins
Non-Executive Director · since 2017
David William Edmund Orr
Non-Executive Director · since 2015
Headquarters & legal address
UNIT 1B LYNX BUSINESS PARK
FORDHAM ROAD, SNAILWELL
NEWMARKET, CAM CB8 7NY
GB
FORDHAM ROAD, SNAILWELL
NEWMARKET, CAM CB8 7NY
GB
Trading name
TRISTEL
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||